| 声称可延缓阿尔茨海默病进程的药物获FDA批准 |
| |
| 引用本文： | 胡静.声称可延缓阿尔茨海默病进程的药物获FDA批准[J].求学,2023(18):69-70. |
| |
| 作者姓名： | 胡静 |
| |
| 作者单位： | 大庆铁人中学 |
| |
| 摘 要： | <正>In early July, FDA granted traditional full approval of Leqembi for the treatment of Alzheimer’s disease(AD). This is the first approved medication proven to slow the progression of AD’s clinical symptoms. A phase three trial among 50-to 90-year-old patients with early AD showed that it can do so by about 27% over an 18-month period. While we cannot extrapolate(推断) beyond 18 months, this represents about a six-month delay in progression of AD symptoms.
|
|
|
